EVL Stock Chart & Stats
€3.88
-€0.10(-0.96%)
At close: 4:00 PM EST
€3.88
-€0.10(-0.96%)
Day’s Range― - ―
52-Week Range€3.42 - €8.15
Previous CloseN/A
Volume0.00
Average Volume (3M)179.00
Market Cap
€324.08M
Enterprise Value€383.03
Total Cash (Recent Filing)€49.79M
Total Debt (Recent Filing)€164.90M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding65,854,750
10 Day Avg. Volume20
30 Day Avg. Volume179
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.67Price Target Upside226.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€290.13M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin SustainabilityMulti-year revenue expansion (+155% TTM) combined with a sustained ~65% gross margin indicates durable product economics and pricing power for Jeuveau. Strong top-line momentum and high gross margins support long-term ability to fund SG&A and product investment while preserving unit-level profitability.
Profitability Momentum And Credible GuidanceBack-to-back positive adjusted EBITDA and management's reiterated 2026 guidance reflect improving operating leverage and disciplined expense management. This shows the business is moving from cash-burning scale to structural profitability under current cost plans, reducing the ongoing need for dilutive financing if execution continues.
Portfolio Diversification Via Profhilo U.S. DealThe IBSA Profhilo distribution deal expands Evolus beyond neurotoxins and fillers into skin-quality injectables via a capital-efficient model. No upfront/ milestone payments and transfer-pricing reduce near-term cash strain while materially broadening the addressable market and practitioner offering, supporting longer-term revenue diversification.
Bears Say
Weak Capitalization / Negative EquityNegative shareholders' equity and elevated debt levels constrain financial flexibility and increase refinancing and covenant risk. A levered balance sheet limits the company's ability to invest opportunistically, absorb shocks or fund launches internally, forcing reliance on external capital during adverse markets.
Persistent Negative Cash GenerationSustained negative operating and free cash flow means Evolus funds operations externally rather than internally generating cash, heightening refinancing risk and constraining self-funded growth. Even with improvement from peak burn, continued negative FCF undermines long-term self-sufficiency for launches and commercialization.
Product Concentration And Competitive PressureRevenue remains concentrated in Jeuveau while Evolisse contribution is small and the filler market is flat. New entrants and incumbent competition can pressure share and require sustained sales investment. Slow diversification increases exposure to competitive or regulatory shocks in the core neurotoxin market.
Evolus News
EVL FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was €3.42 and its highest was €8.15 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is €324.08M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 18 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.099 by €0.059.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.099. Following the earnings report the stock price went up 5.12%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in DE:EVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.67 (226.61% Upside)
€12.67 (226.61% Upside)
Blogger Sentiment
Bullish
DE:EVL Sentiment 70%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.80%
12-Months-Change
Fundamentals
Return on Equity
174.92%
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EVL Stock 12 Month Forecast
Average Price Target
€12.67
▲(226.61% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―